Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Other Non-Current Assets (2016 - 2025)

Fortress Biotech (FBIO) has 13 years of Other Non-Current Assets data on record, last reported at $1.2 million in Q3 2025.

  • For Q3 2025, Other Non-Current Assets fell 63.53% year-over-year to $1.2 million; the TTM value through Sep 2025 reached $1.2 million, down 63.53%, while the annual FY2024 figure was $1.6 million, 36.34% down from the prior year.
  • Other Non-Current Assets reached $1.2 million in Q3 2025 per FBIO's latest filing, roughly flat from $1.2 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $3.4 million in Q2 2024 and bottomed at $1.2 million in Q4 2021.
  • Average Other Non-Current Assets over 5 years is $2.0 million, with a median of $2.2 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 37.69% in 2024, then tumbled 63.66% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.2 million in 2021, then skyrocketed by 85.31% to $2.2 million in 2022, then increased by 9.82% to $2.4 million in 2023, then plummeted by 36.34% to $1.6 million in 2024, then fell by 21.39% to $1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $1.2 million in Q3 2025, $1.2 million in Q2 2025, and $1.2 million in Q1 2025.